Dutacatib
Dutacatib is inhibitor for SARS-CoV-2 3CLpro and cathepsin K, which exhibits antiviral activity and ameliorates the cancer-induced bone diseases.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 501000-36-8
- Formule: C23H31N7O
- Masse moléculaire:421.54
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform Cathepsin
More
Activité biologique
Description
Chemical Information
-
CAS No. 501000-36-8
-
Masse moléculaire 421.54
-
Formule C23H31N7O
-
SMILES
O=C(NCC1=CN=C(C#N)N=C1NCC(C)(C)C)C2=CC=C(N3CCN(C)CC3)C=C2
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Pureté et documentation
Références
[1]. Sousa S, et al., Bone-Targeted Therapies in Cancer-Induced Bone Disease. Calcif Tissue Int. 2018 Feb;102(2):227-250. [Content Brief]
[2]. Dayan Elshan NGR, et al., Discovery of CMX990: A Potent SARS-CoV-2 3CL Protease Inhibitor Bearing a Novel Warhead. J Med Chem. 2024 Feb 22;67(4):2369-2378. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Dutacatib Related Classifications
HY-100701 Related Classifications
Powered by Bioz